Figure 6.

The level of RPS6 is reduced by gefitinib/SU11274 combination in a proteasome-independent manner. (A) HS578T and MDA-MB-231 cells were treated with either DMSO or gefitinib/SU11274 combination (10 μM, respectively) for indicated time and western blot analysis was performed with indicated antibodies. β-actin was used as a loading control. (B) HS578T and MDA-MB-231 cells were treated with compounds as indicated in the absence or presence of 10 μM of MG132 for 4 h and western blot analysis was performed with indicated antibodies. β-actin was used as a loading control.